最新报道:Novo Nordisk will cut 9,000 jobs by 2026 as part of a restructuring plan to save $1.25 billion annually amid falling revenues due to compounded copycat drugs from rivals like Eli Lilly and slowing sales in its obesity and diabetes franchises. The company's stock has dropped nearly 60% this year, from $638 to $350 in September. New CEO Mike Doustdar aims to simplify operations and refocus resources on growth areas rather than just cost-cutting.